These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25999720)

  • 21. Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial.
    Mao JJ; Xie SX; Keefe JR; Soeller I; Li QS; Amsterdam JD
    Phytomedicine; 2016 Dec; 23(14):1735-1742. PubMed ID: 27912875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-Antidepressant Treatment of Generalized Anxiety Disorder.
    Zahreddine N; Richa S
    Curr Clin Pharmacol; 2015; 10(2):86-96. PubMed ID: 23438725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. α
    M'Dahoma S; Poitevin M; Dabala E; Payan H; Gabriel C; Mocaër E; Bourgoin S; Hamon M
    Front Pharmacol; 2018; 9():587. PubMed ID: 29930510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Agomelatine: a novel antidepressant.
    Sansone RA; Sansone LA
    Innov Clin Neurosci; 2011 Nov; 8(11):10-4. PubMed ID: 22191083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders.
    Savino R; Polito AN; Marsala G; Ventriglio A; Di Salvatore M; De Stefano MI; Valenzano A; Marinaccio L; Bellomo A; Cibelli G; Monda M; Monda V; Messina A; Polito R; Carotenuto M; Messina G
    Brain Sci; 2023 Apr; 13(5):. PubMed ID: 37239206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agomelatine in unipolar depression in clinical practice: a retrospective chart review.
    Langan J; Shajahan P; Martin D; Carleton R
    Ther Adv Psychopharmacol; 2011 Dec; 1(6):175-80. PubMed ID: 23983944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pregabalin for the treatment of generalized anxiety disorder: an update.
    Baldwin DS; Ajel K; Masdrakis VG; Nowak M; Rafiq R
    Neuropsychiatr Dis Treat; 2013; 9():883-92. PubMed ID: 23836974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agomelatine: A novel melatonergic antidepressant.
    Manikandan S
    J Pharmacol Pharmacother; 2010 Jul; 1(2):122-3. PubMed ID: 21350627
    [No Abstract]   [Full Text] [Related]  

  • 29. Agomelatine-Induced Maculopapular Rash: A Case Report.
    Okan Ibiloğlu A; Tamam L
    Noro Psikiyatr Ars; 2013 Dec; 50(4):379-380. PubMed ID: 28360575
    [No Abstract]   [Full Text] [Related]  

  • 30. Agomelatine and migraine management: a successfully treated case series.
    Plasencia-García BO; Romero-Guillena SL; Quirós-López A; Ruiz-Doblado S
    Ther Adv Psychopharmacol; 2015 Aug; 5(4):243-5. PubMed ID: 26301081
    [No Abstract]   [Full Text] [Related]  

  • 31. Agomelatine - is it another reboxetine? Another case of publication bias.
    Gupta S
    Psychiatr Bull (2014); 2014 Apr; 38(2):88. PubMed ID: 25237511
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial.
    Kang R; He Y; Yan Y; Li Z; Wu Y; Guo X; Liang Z; Jiang J
    Neuropsychiatr Dis Treat; 2015; 11():1307-11. PubMed ID: 26064049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of long-term agomelatine treatment on the cognitive performance and hippocampal plasticity of adult rats.
    Demir Özkay Ü; Söztutar E; Can ÖD; Üçel Uİ; Öztürk Y; Ulupinar E
    Behav Pharmacol; 2015 Aug; 26(5):469-80. PubMed ID: 26110225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia.
    Gupta S; Singh P; Sharma BM; Sharma B
    Curr Neurovasc Res; 2015; 12(3):240-52. PubMed ID: 26036976
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature.
    Carvalho AF; Sharma MS; Brunoni AR; Vieta E; Fava GA
    Psychother Psychosom; 2016; 85(5):270-88. PubMed ID: 27508501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review.
    Perna G; Alciati A; Riva A; Micieli W; Caldirola D
    Curr Psychiatry Rep; 2016 Mar; 18(3):23. PubMed ID: 26830881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychiatric disorders and sexual dysfunction.
    Waldinger MD
    Handb Clin Neurol; 2015; 130():469-89. PubMed ID: 26003261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
    Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drugs for the treatment of anxiety.
    Murrough JW; Yaqubi S; Sayed S; Charney DS
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):393-406. PubMed ID: 26012843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does melatonin treatment change emotional processing? Implications for understanding the antidepressant mechanism of agomelatine.
    Pringle A; Bogdanovskaya M; Waskett P; Zacharia S; Cowen PJ; Harmer CJ
    J Psychopharmacol; 2015 Oct; 29(10):1129-32. PubMed ID: 26174133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.